On August 23, 2012, Buhr, Wilm; Burckhardt, Susanna; Duerrenberger, Franz; Funk, Felix; Geisser, Peter Otto; Corden, Vincent Anthony; Courtney, Stephen Martin; Davenport, Tara; Slack, Mark; Ridgill, Mark Peter; Yarnold, Christopher John; Dawson, Graham; Boyce, Susan; Ellenbroek, Albertus Antonius published a patent.Electric Literature of 82711-97-5 The title of the patent was Novel sulfonaminoquinoline derivatives as hepcidin antagonists and their preparation and use in the treatment of iron metabolic disorders. And the patent contained the following:
The invention is related to the preparation of title compounds I [R1-6 = independently H, halo, CN, (un)substituted aroxy, heterocyclyl, etc.; R7 = H, (un)substituted alk(en/yn)yl, aryl, etc.; R8 = H, NH2 and derivatives, OH and derivatives, etc.; or R6 and R8 together form a residue II or III; X = C, N; R9-12 = independently H, NO2, CO2H and derivatives, etc.; R13 = H, (un)substituted aryl, acyl, alkyl, etc.; R14, R15 = H, halo, (un)substituted alkoxycarbonyl, aminosulfonyl, etc.] and their pharmaceutically acceptable salts as hepcidin antagonists, pharmaceutical compositions containing them, and to their use as medicaments, in particular for treating iron metabolism disorders, for example, iron deficiency diseases and anemias, in particular anemias combined with chronic inflammation diseases and anemia of inflammation. Thus, reaction of 7-methyl-8-nitroquinoline with 1,1-dimethoxy-N,N-dimethylmethanamine, oxidation of dimethyl[(E)-2-(8-nitroquinolin-7-yl)ethenyl]amine, reductive amination of 8-nitroquinoline-7-carboxaldehyde with aniline, Pd/C hydrogenation of N-[(8-nitroquinolin-7-yl)methyl]phenylamine and cyclization of [7-[(phenylamino)methyl]quinolin-8-yl]amine with 1-[(1H-imidazol-1-yl)sulfonyl]-3-methyl-1H-imidazol-3-ium trifluoromethanesulfonate gave IV. Selected I were evaluated for their hepcidin antagonistic activity. From the assay, it was determined that compound IV exhibited an IC50 value of 0.46 μM towards ferroportin. The experimental process involved the reaction of 5-Fluoro-2-nitrobenzene-1-sulfonyl chloride(cas: 82711-97-5).Electric Literature of 82711-97-5
The Article related to sulfonaminoquinoline preparation hepcidin antagonist treatment iron metabolic disorder, dioxothiatriazaphenanthrene dioxothiadiazachrysene dioxoazacyclopentanaphthalene dioxothiatriazachrysene preparation anemia hepcidin antagonist and other aspects.Electric Literature of 82711-97-5
Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics